• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于研究人组织激肽释放酶hK1和hK2底物特异性的丝氨酸蛋白酶抑制剂衍生肽底物。

Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.

作者信息

Bourgeois L, Brillard-Bourdet M, Deperthes D, Juliano M A, Juliano L, Tremblay R R, Dubé J Y, Gauthier F

机构信息

Laboratory of Enzymology and Protein Chemistry, CNRS EP 117, University François Rabelais, 37032 Tours, France.

出版信息

J Biol Chem. 1997 Nov 21;272(47):29590-5. doi: 10.1074/jbc.272.47.29590.

DOI:10.1074/jbc.272.47.29590
PMID:9368023
Abstract

The third human tissue kallikrein to be identified, hK2, could be an alternate or complementary marker to kallikrein hK3 (prostate-specific antigen) for prostate diseases. Most of the hK2 in seminal plasma forms an inactive complex with protein C inhibitor (PCI), a serpin secreted by seminal vesicles. As serpin inhibitors behave as suicide substrates that are cleaved early in the interaction with their target enzyme, and kallikreins have different sensitivities to serpin inhibitors, we prepared a series of substrates with intramolecularly quenched fluorescence based on the sequences of the serpin reactive loops. They were used to compare the substrate specificities of hK1 and hK2, which both have trypsin-like specificity, and thus differ from chymotrypsin-like hK3. The serpin-derived peptides behaved as kallikrein substrates whose sensitivities reflected the specificity of the parent inhibitory proteins. Substrates derived from PCI were the most sensitive for both hK1 and hK2 with specificity constants of about 10(7) M-1. s-1. Those derived from antithrombin III and alpha2-antiplasmin were more specific for hK2 while a kallistatin-derived substrate was specifically cleaved by hK1. hK1 and hK2 substrates of greater specificity were obtained using chimeric peptides based on the sequence of serpin reactive loops. The main difference between specificities of hK1 and hK2 arise because hK2 can accommodate positively charged as well as small residues at P2 and requires an arginyl residue at P1. Thus, unlike hK1, hK2 does not cleave kininogen-derived substrates overlapping the region of N-terminal insertion of bradykinin in human kininogens.

摘要

第三种被鉴定出的人体组织激肽释放酶hK2,可能是前列腺疾病中激肽释放酶hK3(前列腺特异性抗原)的替代或补充标志物。精浆中的大多数hK2与蛋白C抑制剂(PCI)形成无活性复合物,PCI是精囊分泌的一种丝氨酸蛋白酶抑制剂。由于丝氨酸蛋白酶抑制剂作为自杀底物,在与靶酶相互作用的早期就被裂解,并且激肽释放酶对丝氨酸蛋白酶抑制剂具有不同的敏感性,我们基于丝氨酸蛋白酶抑制剂反应环的序列制备了一系列具有分子内猝灭荧光的底物。它们被用于比较hK1和hK2的底物特异性,这两种酶都具有胰蛋白酶样特异性,因此不同于糜蛋白酶样的hK3。丝氨酸蛋白酶抑制剂衍生的肽表现为激肽释放酶底物,其敏感性反映了母体抑制蛋白的特异性。源自PCI的底物对hK1和hK2最为敏感,特异性常数约为10(7) M-1·s-1。源自抗凝血酶III和α2-抗纤溶酶的底物对hK2更具特异性,而源自激肽释放酶抑制蛋白的底物则被hK1特异性裂解。基于丝氨酸蛋白酶抑制剂反应环序列的嵌合肽可获得特异性更高的hK1和hK2底物。hK1和hK2特异性的主要差异在于,hK2在P2位点既能容纳带正电荷的残基,也能容纳小的残基,并且在P1位点需要一个精氨酰残基。因此,与hK1不同,hK2不会裂解与人激肽原中缓激肽N端插入区域重叠的激肽原衍生底物。

相似文献

1
Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.用于研究人组织激肽释放酶hK1和hK2底物特异性的丝氨酸蛋白酶抑制剂衍生肽底物。
J Biol Chem. 1997 Nov 21;272(47):29590-5. doi: 10.1074/jbc.272.47.29590.
2
Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.从精液中纯化得到的前列腺源性人腺体激肽释放酶(hK2)的激肽原酶活性。
J Androl. 1999 Mar-Apr;20(2):220-9.
3
Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein.用于研究大鼠组织激肽释放酶血管活性特性的激肽原衍生荧光底物——一种释放T激肽的大鼠激肽释放酶的鉴定
Eur J Biochem. 1997 Jul 15;247(2):652-8. doi: 10.1111/j.1432-1033.1997.00652.x.
4
Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none.人激肽释放酶hK2具有低激肽原酶活性,而前列腺特异性抗原(hK3)则没有。
Biochim Biophys Acta. 1997 Nov 14;1343(1):102-6. doi: 10.1016/s0167-4838(97)00135-0.
5
Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.人腺体激肽释放酶2(hK2)的酶促作用。底物特异性以及锌离子和细胞外蛋白酶抑制剂的调节作用。
Eur J Biochem. 1999 Jun;262(3):781-9. doi: 10.1046/j.1432-1327.1999.00433.x.
6
Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.人腺体激肽释放酶hK2表现出对精氨酸的限制性特异性,并与血浆蛋白酶抑制剂形成复合物。
Prostate. 1998 Jan 1;34(1):44-50. doi: 10.1002/(sici)1097-0045(19980101)34:1<44::aid-pros6>3.0.co;2-k.
7
Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.人组织激肽释放酶对含苯丙氨酸-苯丙氨酸氨基酸对底物的特异性。
Biochem J. 1999 Apr 15;339 ( Pt 2)(Pt 2):473-9.
8
Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors.利用激肽释放酶抑制蛋白的反应中心环研究人组织激肽释放酶S'1和S'2亚位点的特异性:P'1和P'2位点在抑制剂设计中的重要性。
Biochem J. 2003 May 1;371(Pt 3):1021-5. doi: 10.1042/BJ20021952.
9
Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins.人、小鼠和大鼠组织激肽释放酶在底物和抑制剂序列特异性上的差异。
Biochem J. 2004 Jun 15;380(Pt 3):775-81. doi: 10.1042/BJ20031047.
10
A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.激肽释放酶抑制蛋白表面带正电荷的环,作为激肽释放酶的二级结合位点,发挥增强组织激肽释放酶抑制作用。
J Biol Chem. 2000 Dec 22;275(51):40371-7. doi: 10.1074/jbc.M005691200.

引用本文的文献

1
Crucial role of estrogen for the mammalian female in regulating semen coagulation and liquefaction in vivo.雌激素对哺乳动物雌性在体内调节精液凝固和液化方面起着关键作用。
PLoS Genet. 2017 Apr 17;13(4):e1006743. doi: 10.1371/journal.pgen.1006743. eCollection 2017 Apr.
2
Effects of urine composition on epithelial Na+ channel-targeted protease activity.尿液成分对上皮钠通道靶向蛋白酶活性的影响。
Physiol Rep. 2015 Nov;3(11). doi: 10.14814/phy2.12611.
3
Unleashing the therapeutic potential of human kallikrein-related serine proteases.
释放人激肽释放酶相关丝氨酸蛋白酶的治疗潜力。
Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20.
4
Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.人激肽释放酶相关肽酶2的结构-功能分析确定99环为活性的主要调节因子。
J Biol Chem. 2014 Dec 5;289(49):34267-83. doi: 10.1074/jbc.M114.598201. Epub 2014 Oct 16.
5
Activatable Optical Probes for the Detection of Enzymes.用于酶检测的可激活光学探针。
Curr Org Synth. 2011 Aug;8(4):498-520. doi: 10.2174/157017911796117232.
6
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).激肽释放酶相关肽酶(KLKs)的天然和合成抑制剂。
Biochimie. 2010 Nov;92(11):1546-67. doi: 10.1016/j.biochi.2010.06.022. Epub 2010 Jul 6.
7
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.使用一组血清蛋白质组学生物标志物预测前列腺癌生化复发
J Urol. 2009 Mar;181(3):1407-14. doi: 10.1016/j.juro.2008.10.142. Epub 2009 Jan 20.
8
Human seminal proteinase and prostate-specific antigen are the same protein.人精浆蛋白酶和前列腺特异性抗原是同一种蛋白质。
J Biosci. 2008 Jun;33(2):195-207. doi: 10.1007/s12038-008-0037-4.
9
Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans.人类组织激肽释放酶活性部分基因缺陷的动脉和肾脏后果。
J Clin Invest. 2005 Mar;115(3):780-7. doi: 10.1172/JCI23669.
10
Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins.人、小鼠和大鼠组织激肽释放酶在底物和抑制剂序列特异性上的差异。
Biochem J. 2004 Jun 15;380(Pt 3):775-81. doi: 10.1042/BJ20031047.